Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

Saved in:
Bibliographic Details
Title: Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.
Authors: Moore CG; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Chyong DI; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Daver N; MD Anderson Cancer Center, Houston, Texas, USA., Aubrey BJ; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Marx KR; MD Anderson Cancer Center, Houston, Texas, USA., Takahashi K; MD Anderson Cancer Center, Houston, Texas, USA., Abaza Y; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Smith CC; University of California San Francisco, San Francisco, California, USA., Amrein PC; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Hock H; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Hobbs G; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Narayan R; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Lee MH; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Moran JA; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Bergeron M; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Foster JE; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Perl AE; University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA., Levis MJ; Johns Hopkins Cancer Center, Baltimore, Maryland, USA., DiNardo CD; MD Anderson Cancer Center, Houston, Texas, USA., Brunner AM; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Fathi AT; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Source: British journal of haematology [Br J Haematol] 2026 Jul 12. Date of Electronic Publication: 2026 Jul 12.
Publication Type: Journal Article
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1365-2141
DOI:10.1111/bjh.70671